摘要
目的观察替比夫定联合阿德福韦酯长期使用治疗活动性乙肝肝硬化患者的临床疗效。方法纳入我院收治的72例活动性乙肝肝硬化患者参与临床研究,并将72例患者随机分为联合组和单一组,给予联合组患者替比夫定、阿德福韦酯联合治疗,给予单一组患者阿德福韦酯治疗。结果治疗前两组患者的肝功能比较无明显差异,P>0.05,治疗后联合组患者的肝功能优于单一组,P<0.05,HBV-DNA转阴率较单一组患者高,P<0.05,两组不良反应发生率比较不存在明显差异,P>0.05。结论替比夫定联合阿德福韦酯长期使用治疗活动性乙肝肝硬化患者,疗效安全可靠。
Objective： To evaluate telbivudine combined with adefovir dipivoxil long-term clinical efficacy of treatment of active hepatitis B patients with cirrhosis. Methods： 72 case of patients admitted to hospital with active hepatitis B pa- tients with cirrhosis participate in clinical research, and 72 patients were randomly divided into combination group and a single group, the combined group of patients received telbivudine, adefovir combination therapy, a single group of patients recevied administered adefovir therapy. Results ： There was no pre-treatment liver function in patients with significant differ- ence between the two groups, P 〉 0. 05, after treatment, the combined group of patients with liver function better than a sin- gle group ,P 〈 0. 05, HBV-DNA negative rate higher than a single group of patients ,P 〈 0.05, two groups in the incidence of adverse reactions there is no significant difference,P 〉 O. 05. Conclusion： Telbivudine combined with adefovir dipivoxil long-term treatment of active hepatitis B patients with cirrhosis, safe and reliable effect.
出处
《泰山医学院学报》
CAS
2017年第4期385-386,共2页
Journal of Taishan Medical College
基金
广东省自然科学基金-自由申请基金(项目编号:2015A030313803)
